Printer Friendly

Merck reaches settlement over Vioxx in Canada.

M2 PHARMA-January 20, 2012-Merck reaches settlement over Vioxx in Canada(C)2012 M2 COMMUNICATIONS

20 January 2012 - Merck & Co Inc (NYSE:MRK) said on Thursday that it had signed an agreement to settle all claims related to its Vioxx drug in Canada.

The agreement with representatives of the plaintiffs is still subject to approval by courts in Canada's provinces.

If the agreement receives court approval, Merck will pay between CAD21.8m (USD21.6m/EUR16.7m) and CAD36.9m to resolve all certified class actions, putative class actions, other litigation and claims related to Vioxx in Canada.

The amount allocated for Vioxx users in Canada will be between CAD11.3m and CAD26.4m depending on the final number of eligible claims.

The settlement agreement also includes fixed costs of CAD6m for class counsel fees, CAD3.5m for provinces and territories and CAD1m for administrative expenses.

(CAD1 = USD0.987/EUR0.761)

((Comments on this story may be sent to

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:1CANA
Date:Jan 20, 2012
Previous Article:Neurocrine Biosciences prices stock offer, seeks USD77m in gross proceeds.
Next Article:Mylan launches antiepileptic drug in sodium chloride injection in multiple strengths.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters